Methoxsalen Macopharma (Methoxsalen)

After exposure to UVA radiation, methoxsalen intercalates into DNA and creates cross‑links that inhibit DNA synthesis. This suppresses the rapid growth of skin cells and modulates immune activity, leading to clinical improvement in targeted dermatologic conditions.

The specific dose and treatment schedule of methoxsalen are determined by the prescribing clinician based on the patient’s condition, skin type, and response to UVA exposure. Dosage is individualized and should follow the prescriber’s instructions.

Safety data for methoxsalen in pregnancy and lactation are limited, and the pregnancy category is unknown. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Methoxsalen is the most commonly used psoralen for PUVA therapy, offering a well‑characterized safety and efficacy profile. Alternative psoralens exist but are less widely studied; methoxsalen’s pharmacokinetics and interaction profile are better defined, making it the standard choice in many clinical settings.

Methoxsalen should be stored at room temperature, below 25 °C, in its original packaging. Protect the product from moisture and direct light to maintain stability. No refrigeration is required for this formulation.

Methoxsalen is administered extracorporeally, typically as a topical or oral preparation taken prior to controlled UVA exposure in a clinical setting. The exact route and timing are determined by the treating physician and the specific PUVA protocol used.

Serious risks include severe phototoxic reactions such as blistering or burns, ocular toxicity leading to cataracts, bone marrow suppression, and a potential increased long‑term risk of skin cancer. Patients should be monitored closely for these adverse events.

Methoxsalen is contraindicated in individuals with porphyria, known hypersensitivity to psoralens, or those who cannot avoid UVA exposure. It should also be used with caution in patients with significant liver disease or impaired renal function.